{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:33:15Z","timestamp":1704702795506},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00105-022-05071-9","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T17:03:11Z","timestamp":1668531791000},"page":"965-972","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eosinophile Dermatosen"],"prefix":"10.1007","volume":"73","author":[{"given":"E.","family":"Papakonstantinou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. M.","family":"Limberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. F. H.","family":"Diercks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Raap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"issue":"2","key":"5071_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jaci.2021.11.012","volume":"149","author":"JLM Dunn","year":"2022","unstructured":"Dunn\u00a0JLM, Rothenberg\u00a0ME (2022) 2021\u00a0year in review: Spotlight on eosinophils. J\u00a0Allergy Clin Immunol 149(2):517\u2013524","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"5071_CR2","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaip.2020.10.048","volume":"9","author":"AN Pepper","year":"2021","unstructured":"Pepper\u00a0AN et\u00a0al (2021) How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. J\u00a0Allergy Clin Immunol Pract 9(3):1081\u20131088","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"5071_CR3","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.5415\/apallergy.2022.12.e25","volume":"12","author":"CK Kim","year":"2022","unstructured":"Kim\u00a0CK et al (2022) Increase in eosinophil-derived neurotoxin level in school children with allergic disease. Asia Pac Allergy 12(3):e25","journal-title":"Asia Pac Allergy"},{"key":"5071_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/all.15481","volume-title":"Urine eosinophil-derived neurotoxin: a\u00a0potential marker of activity in select eosinophilic disorders. Allergy","author":"MA Makiya","year":"2022","unstructured":"Makiya MA et al (2022) Urine eosinophil-derived neurotoxin: a\u00a0potential marker of activity in select eosinophilic disorders. Allergy. https:\/\/doi.org\/10.1111\/all.15481"},{"key":"5071_CR5","doi-asserted-by":"publisher","first-page":"627985","DOI":"10.3389\/fmed.2021.627985","volume":"8","author":"A Ruppenstein","year":"2021","unstructured":"Ruppenstein\u00a0A et al (2021) Involvement of neuro-immune interactions in pruritus with special focus on receptor expressions. Front Med 8:627985","journal-title":"Front Med"},{"key":"5071_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","volume":"3","author":"C Lombardi","year":"2022","unstructured":"Lombardi\u00a0C, Berti\u00a0A, Cottini\u00a0M (2022) The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol 3:42\u201353","journal-title":"Curr Res Immunol"},{"key":"5071_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01291-2","author":"S Grisaru-Tal","year":"2022","unstructured":"Grisaru-Tal S, Rothenberg ME, Munitz A (2022) Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nat Immunol. https:\/\/doi.org\/10.1038\/s41590-022-01291-2","journal-title":"Nat Immunol"},{"issue":"1","key":"5071_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/JLB.3MR1117-426R","volume":"104","author":"MG Drake","year":"2018","unstructured":"Drake\u00a0MG et\u00a0al (2018) Eosinophil and airway nerve interactions in asthma. J\u00a0Leukoc Biol 104(1):61\u201367","journal-title":"J Leukoc Biol"},{"issue":"5","key":"5071_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/cea.13560","volume":"50","author":"D Guseva","year":"2020","unstructured":"Guseva\u00a0D et al (2020) Neuronal branching of sensory neurons is associated with BDNF-positive eosinophils in atopic dermatitis. Clin Exp Allergy 50(5):577\u2013584","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"5071_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.coi.2012.08.010","volume":"24","author":"S Yousefi","year":"2012","unstructured":"Yousefi\u00a0S, Simon\u00a0D, Simon\u00a0HU (2012) Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol 24(6):736\u2013739","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"5071_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jaip.2022.02.006","volume":"10","author":"MM Chen","year":"2022","unstructured":"Chen\u00a0MM et al (2022) An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes. J\u00a0Allergy Clin Immunol Pract 10(5):1217\u20131228.e3","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"5071_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","volume":"137","author":"B King","year":"2017","unstructured":"King\u00a0B, Lee\u00a0AI, Choi\u00a0J (2017) Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J\u00a0Invest Dermatol 137(4):951\u2013954","journal-title":"J Invest Dermatol"},{"key":"5071_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.04.037","author":"ME Rothenberg","year":"2022","unstructured":"Rothenberg ME et al (2022) Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and Interleukin\u20115. J\u00a0Allergy Clin Immunol Pract. https:\/\/doi.org\/10.1016\/j.jaip.2022.04.037","journal-title":"Allergy"},{"key":"5071_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15799","author":"OC Trica","year":"2022","unstructured":"Trica OC, Mocan LP, Boit-Trapcea R (2022) Mepolizumab is highly effective in a\u00a0rare case of Wells syndrome\u2014eosinophilic granulomatosis with polyangiitis overlap. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15799","journal-title":"Dermatol Ther"},{"issue":"7","key":"5071_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ddg.14151","volume":"18","author":"D Terhorst-Molawi","year":"2020","unstructured":"Terhorst-Molawi\u00a0D et al (2020) Effective treatment with mepolizumab in a\u00a0patient with refractory Wells syndrome. J\u00a0Dtsch Dermatol Ges 18(7):737\u2013739","journal-title":"J Dtsch Dermatol Ges"},{"key":"5071_CR16","first-page":"22","volume":"e932888","author":"SH Boppana","year":"2021","unstructured":"Boppana\u00a0SH et al (2021) Drug-associated eosinophilic fasciitis: a case of eosinophilic fasciitis secondary to cemiplimab therapy. Am J Case Rep e932888:22","journal-title":"Am J Case Rep"},{"issue":"6","key":"5071_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/ijd.16003","volume":"61","author":"L Tognetti","year":"2022","unstructured":"Tognetti\u00a0L et al (2022) UVA\u20111 phototherapy as adjuvant treatment for eosinophilic fasciitis: in vitro and in vivo functional characterization. Int J Dermatol 61(6):718\u2013726","journal-title":"Int J Dermatol"},{"key":"5071_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15379","author":"R Xia","year":"2022","unstructured":"Xia R et\u00a0al (2022) Dupilumab use in a\u00a0case of eosinophilic fasciitis. Clin Exp Dermatol. https:\/\/doi.org\/10.1111\/ced.15379","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"5071_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/23971983211004399","volume":"6","author":"P \u015amigielska","year":"2021","unstructured":"\u015amigielska\u00a0P et\u00a0al (2021) Refractory eosinophilic fasciitis successfully treated with infliximab: a case report. J\u00a0Scleroderma Relat Disord 6(2):211\u2013213","journal-title":"J Scleroderma Relat Disord"},{"issue":"6","key":"5071_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3899\/jrheum.200998","volume":"48","author":"R Sehgal","year":"2021","unstructured":"Sehgal\u00a0R, Ernste\u00a0FC, Eckloff\u00a0S (2021) Successful treatment with Baricitinib in a\u00a0patient with refractory eosinophilic fasciitis. J\u00a0Rheumatol 48(6):948\u2013949","journal-title":"J Rheumatol"},{"issue":"7","key":"5071_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.rce.2021.12.002","volume":"222","author":"AM Brandy-Garc\u00eda","year":"2022","unstructured":"Brandy-Garc\u00eda\u00a0AM, Fern\u00e1ndez\u00a0S, Pamp\u00edn-S\u00e1nchez\u00a0R (2022) Tocilizumab in the treatment of eosinophilic fasciitis: case report and literature review. Rev Clin Esp 222(7):440\u2013442","journal-title":"Rev Clin Esp"},{"issue":"10","key":"5071_CR22","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00296-021-04887-3","volume":"41","author":"N Kougkas","year":"2021","unstructured":"Kougkas\u00a0N et al (2021) Rituximab for refractory eosinophilic fasciitis: a\u00a0case series with long-term follow-up and literature review. Rheumatol Int 41(10):1833\u20131837","journal-title":"Rheumatol Int"},{"key":"5071_CR23","first-page":"1","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","author":"N Hunzelmann","year":"2017","unstructured":"Hunzelmann\u00a0N, Krieg\u00a0T (2017) Sklerodermie. In: Plewig\u00a0G, Ruzicka\u00a0T, Kaufmann\u00a0R, Hertl\u00a0M (Hrsg) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie. Springer, Berlin, Heidelberg, S 1\u201318"},{"issue":"1","key":"5071_CR24","doi-asserted-by":"publisher","first-page":"e13162","DOI":"10.1111\/dth.13162","volume":"33","author":"E Alsorori","year":"2020","unstructured":"Alsorori\u00a0E et\u00a0al (2020) A case of granuloma faciale successfully treated with systemic dapsone. Dermatol Ther 33(1):e13162","journal-title":"Dermatol Ther"},{"issue":"2","key":"5071_CR25","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/ijd.14664","volume":"59","author":"FS Gil","year":"2020","unstructured":"Gil\u00a0FS, Parente\u00a0J, Aranha\u00a0J (2020) Resolution of granuloma faciale with topical tacrolimus. Int J Dermatol 59(2):e29\u2013e31","journal-title":"Int J Dermatol"},{"issue":"11","key":"5071_CR26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2018.2681","volume":"154","author":"D Morgado-Carrasco","year":"2018","unstructured":"Morgado-Carrasco\u00a0D et al (2018) Assessment of treatment of refractory granuloma faciale with intralesional rituximab. JAMA Dermatol 154(11):1312\u20131315","journal-title":"JAMA Dermatol"},{"issue":"10","key":"5071_CR27","doi-asserted-by":"publisher","first-page":"e3847","DOI":"10.1097\/GOX.0000000000003847","volume":"9","author":"K Bayne","year":"2021","unstructured":"Bayne\u00a0K et\u00a0al (2021) Successful novel treatment of granuloma faciale using CO(2) emulated Er:YAG laser ablation. Plast Reconstr Surg Glob Open 9(10):e3847","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"5071_CR28","first-page":"1","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","author":"JC Simon","year":"2017","unstructured":"Simon\u00a0JC (2017) Hauterkrankungen mit Eosinophilie. In: Plewig\u00a0G, Ruzicka\u00a0T, Kaufmann\u00a0R, Hertl\u00a0M (Hrsg) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie. Springer, Berlin, Heidelberg, S 1\u20138"},{"issue":"7","key":"5071_CR29","doi-asserted-by":"publisher","first-page":"e15550","DOI":"10.1111\/dth.15550","volume":"35","author":"A Ramondetta","year":"2022","unstructured":"Ramondetta\u00a0A et\u00a0al (2022) A case of eosinophilic pustular folliculitis successfully treated with adalimumab. Dermatol Ther 35(7):e15550","journal-title":"Dermatol Ther"},{"issue":"6","key":"5071_CR30","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1111\/jdv.17181","volume":"35","author":"C B\u00fcrgler","year":"2021","unstructured":"B\u00fcrgler\u00a0C et al (2021) Treatment of eosinophilic pustular folliculitis with benralizumab in a\u00a013-year-old girl. J\u00a0Eur Acad Dermatol Venereol 35(6):e401\u2013e403","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-022-05071-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-022-05071-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T11:05:20Z","timestamp":1669374320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-022-05071-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5071"],"URL":"https:\/\/doi.org\/10.1007\/s00105-022-05071-9","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"30 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>E.\u00a0Papakonstantinou:<\/b> A.\u00a0Finanzielle Interessen: E.\u00a0Papakonstantinou gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Dermatologin, Private Klinik, Dermoiatriki Athinon, Athen Griechenland. <b>J.\u00a0Fischer:<\/b> A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: DFG (offizielle Forschungsf\u00f6rderung). \u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Vortragsreferat Bencard Allergie, ALK-Abell\u00f3 Allergie, Janssen Deutschland, Gesellschaft f\u00fcr experimentelle und klinische Allergieforschung (GEKA), Novartis. \u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt Universit\u00e4tsklinik f\u00fcr Dermatologie und Allergologie, Klinikum Oldenburg A\u00f6R, Oldenburg. <b>M.\u00a0Limberg: <\/b>A.\u00a0Finanzielle Interessen: M.\u00a0Limberg gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Dr. rer. nat., Diplom Biologin, wissenschaftliche Mitarbeiterin, Laborleitung. <b>G.\u00a0Diercks: <\/b>A.\u00a0Finanzielle Interessen: G.\u00a0Diercks gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Pathologist, University Medical Center, Groningen, The Netherlands. <b>B.\u00a0Horvath: <\/b>A.\u00a0Finanzielle Interessen: reports fees from Janssen-Cilag (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), AbbVie (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), Leo Pharma (Consultations), Solenne B.V. (Investigator Initiative Studies), Celgene (Consultations, Investigator Initiative Studies), Akari therapeutics (Consultations, Investigator Initiative Studies), Philips (Consultation), Roche (Consultation), Regeneron (Consultation) and Sanofi (Consultation), Argenx (Advisory Boards, Consultations) which fees were paid to the institution. \u2013 B.\u00a0Nichtfinanzielle Interessen: Head of the Department Dermatology, University Medical Center Groningen, Groningen | Member EADV and member EADV Taskforce on AIBD\/HS, member EHSF; Associate Editor BJD, Editor Springer book: study guide on AIBD (2de edition). <b>U.\u00a0Raap:<\/b> A.\u00a0Finanzielle Interessen: U.\u00a0Raap gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Direktorin der Universit\u00e4tsklinik f\u00fcr Dermatologie und Allergologie, Klinikum Oldenburg, Universit\u00e4tsmedizin Oldenburg.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}